H3B-6527 Inhibitor

Name: H3B-6527 Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5758619
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5758619

H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma, with antineoplastic activity. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

H3B-6527, Inhibitor

Full Product Name

H3B-6527

Product Gene Name

H3B-6527, inhibitor

Form/Format

Solid. Powder

Purity/Purification

99.85%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

629.53

Solubility

DMSO: 2.5mg/mL (3.97mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C29H34Cl2N8O4

SMILES

C=CC(=O)Nc1cc(N2CCN(CC)CC2)ccc1Nc1cc(N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)ncn1

CAS Number

1702259-66-2

Target & IC50

FGFR

Cell Research

Immunohistochemistry and Western blotting were used to detect FGFR4 expression in ESCC samples and cell lines. Cell counting kit-8, and clonogenic, transwell, flow cytometric, and tumor xenograft in nude mice assays were utilized to determine the effect of blocking FGFR4 in proliferation, invasion, migration, and apoptosis of ESCC cells[2].

Product Categories/Family for H3B-6527, inhibitor

Angiogenesis; FGFR; Tyrosine Kinase/Adaptors

Product References and Citations for H3B-6527, inhibitor

Joshi, Jaya Julie, Coffey, Heather, Corcoran, Erik,et al. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma[J]. Cancer Research, 77(24):6999-7013.
Joshi, Jaya Julie, Coffey, Heather, Corcoran, Erik,et al. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma[J]. Cancer Research, 77(24):6999-7013.
Zhongwei, Xin, Xuemin, et al. Blocking FGFR4 exerts distinct anti-tumorigenic effects in esophageal squamous cell carcinoma.[J]. Thoracic cancer, 2018.
Zhongwei, Xin, Xuemin, et al. Blocking FGFR4 exerts distinct anti-tumorigenic effects in esophageal squamous cell carcinoma.[J]. Thoracic cancer, 2018.
Joshi JJ, et al. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven HepatocellularCarcinoma. Cancer Res. 2017 Dec 15;77(24):6999-7013.

Other Notes

Small volumes of H3B-6527, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for H3B-6527 purchase

MBS5758619 is an inhibitor targeting H3B-6527.